Abstract
This study identifies ubiquitous mitochondrial creatine kinase (uMtCK) as a pivotal driver of gastric cancer (GC) metastasis. By activating the JNK-MAPK/JUN signaling pathway, uMtCK upregulates Hexokinase 2 (HK2), thereby enhancing glycolytic flux and promoting aggressive cell migration and invasion. This article presents corrected figures for migration and invasion assays, reinforcing the role of the uMtCK/HK2 axis in GC progression and its impact on overall survival in animal models.
Introduction
Gastric cancer remains a leading cause of cancer-related mortality worldwide, largely due to its high metastatic potential. A hallmark of such aggressive cancers is "metabolic reprogramming," where cells alter their energy production—often favoring glycolysis even in the presence of oxygen (the Warburg effect)—to support rapid growth and movement. This research sought to understand the role of uMtCK, an enzyme typically involved in maintaining cellular ATP homeostasis, in this process. While uMtCK is known to function in the mitochondria, its specific contribution to the signaling pathways that regulate glycolysis and metastasis in gastric cancer was previously unclear.
Methodology
The authors employed a combination of in vitro and in vivo techniques to map the uMtCK signaling axis. The study utilized two gastric cancer cell lines, AGS and SGC-7901. Genetic manipulation was achieved using lentiviral vectors for overexpression (Lv-uMtCK) and small interfering RNA (si-uMtCK) or short hairpin RNA (sh-HK2) for gene knockdown. Functional assays included wound-healing assays to measure collective cell migration and Transwell migration and invasion assays to quantify individual cell movement. In vivo metastasis was modeled by injecting engineered GC cells into the spleens of nude mice, with progression monitored via bioluminescence imaging and histological analysis of liver tissues.
Key Results
uMtCK as a Metastatic Driver
The study's most critical insight is that uMtCK is a proactive driver of metastasis. Overexpressing uMtCK significantly increased the number of migrated and invasive cells, while knocking it down had the opposite effect. In AGS cells, uMtCK overexpression nearly doubled the percentage of wound closure and significantly increased the number of invaded cells compared to controls.
In Vivo Metastasis and Survival
In the mouse model, cells overexpressing uMtCK formed significantly more metastatic lesions in the liver. Conversely, uMtCK knockdown (si-uMtCK) drastically reduced the metastatic burden. Mice injected with uMtCK-overexpressing cells showed significantly shorter overall survival (OS) compared to the control group.
The HK2 Dependency and Signaling Bridge
The researchers identified the JNK-MAPK/JUN axis as the bridge between mitochondrial enzyme activity (uMtCK) and nuclear transcriptional control of glycolytic enzymes (HK2). The pro-metastatic effects of uMtCK were found to be strictly dependent on Hexokinase 2 (HK2). Inhibition of migration and invasion caused by uMtCK knockdown could be "rescued" (reversed) by overexpressing HK2, confirming HK2's role as the primary downstream effector.
Conclusion
This study establishes the uMtCK/JNK-MAPK/JUN/HK2 axis as a significant metabolic driver of gastric cancer progression. By connecting mitochondrial metabolism directly to signaling pathways that dictate cell behavior, the findings suggest that targeting this axis could be a viable therapeutic strategy. The corrected figures provided in this notice support the original conclusions and clarify the experimental evidence for migration and invasion assays.
Summary updated